Pharmaceuticals News and Research

RSS

Alza files patent infringement suit against Impax in connection with Concerta

Impax Laboratories, Inc. today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with Concerta® (methylphenidate hydrochloride) extended-release 54 mg tablets.

30 Nov 2010

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.

29 Nov 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

China Pediatric Pharmaceuticals third quarter net sales increase 72% to $7,182,906

China Pediatric Pharmaceuticals, Inc., today announced its financial results for the third quarter ended September 30, 2010. The Company's quarterly report on Form 10-Q was filed with the U.S. Securities Exchange Commission on November 22, 2010.

29 Nov 2010

Weikang anticipates $71 - $82 million revenue for fiscal 2011

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.

29 Nov 2010

Renhuang Pharmaceuticals changes name to China Botanic Pharmaceutical

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company's Articles of Incorporation have been amended to effect the name change of the Company from its former name of Renhuang Pharmaceuticals.

29 Nov 2010

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

29 Nov 2010

Lilly selects Veeva CRM for global deployments

Veeva Systems announced today that its Veeva CRM® suite of applications has been chosen by pharmaceutical company Eli Lilly and Company for major global deployments.

29 Nov 2010

Cardinal Health acquires Zuellig Pharma China for $470 million

Cardinal Health today announced the completion of a $470 million acquisition of privately held Zuellig Pharma China, a leading health care distribution business in China, known locally as Yong Yu, and the largest pharmaceutical importer in the country. The transaction extends Cardinal Health's distribution and services presence into one of the world's fastest growing health care markets and provides a platform to drive long-term growth.

29 Nov 2010

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

29 Nov 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

AMAG updates product label of Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) regarding an update to the product label for Feraheme (ferumoxytol) Injection for intravenous (IV) use.

29 Nov 2010

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.

29 Nov 2010

Tongjitang files going-private statement on Schedule 13E-3 with SEC

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it has filed a going-private transaction statement on Schedule 13E-3 with the United States Securities and Exchange Commission

29 Nov 2010

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited , today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (CRF) patients on dialysis in the United States.

29 Nov 2010

BioTime, CIRM enter agreement for GMP-grade hES cell lines

BioTime, Inc. today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human embryonic stem (hES) cell lines available to California-based researchers. CIRM is the stem cell agency created when California voters supported a $3 billion funding measure for stem cell-related research and clinical translation.

29 Nov 2010

Marcus evans Summit highlights potential growth, innovation in drug discovery

Drug discovery scientists need to broaden their approaches to pharmaceutical research and development (R&D) and Medicinal Chemistry, to take advantage of untapped opportunities, says Torsten Hoffmann, Head Discovery Chemistry at F. Hoffmann La Roche, Basel, Switzerland. Chemical Biology allows room for innovation, but is often overlooked by scientists in the industry.

29 Nov 2010

MEDIAN Technologies receives OSEO 'Innovative Company' accreditation

MEDIAN Technologies, the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, today announced that it had obtained "Innovative Company" accreditation from OSEO (the French state innovation agency). This accreditation enables innovation-focused French investment funds (Fonds Communs de Placement dans l'Innovation) to invest in MEDIAN Technologies and enjoy a number of fiscal advantages.

29 Nov 2010

Thomson Reuters announces acquisition of GeneGo

Thomson Reuters today announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development.

29 Nov 2010

Pharma enhances its focus on Asia-Pacific partnerships

While the Japanese market still dominates deal activities in the Asia-Pacific (APAC) region, companies and research institutes in emerging APAC countries have recently been attracting high calibre collaborators, according to the latest analysis by Datamonitor.

28 Nov 2010